| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Chakma Justin | Chief Business Officer | C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO | /s/ Kathleen Scott, Attorney-in-Fact | 14 Nov 2025 | 0001951238 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Common Stock | Options Exercise | $25.2K | +30K | +22% | $0.84 | 166K | 12 Nov 2025 | Direct | |
| transaction | SPRY | Common Stock | Sale | -$267K | -30K | -18.03% | $8.91 | 136K | 12 Nov 2025 | Direct | F1 |
| transaction | SPRY | Common Stock | Sale | -$1.21M | -136K | -100% | $8.86 | 0 | 12 Nov 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPRY | Stock Option (Right to Buy) | Options Exercise | $0 | -30K | -25.2% | $0.00 | 89K | 12 Nov 2025 | Common Stock | 30K | $0.84 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| F2 | The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| F3 | Immediately exercisable. |